|
EP0920339A2
(en)
*
|
1996-07-09 |
1999-06-09 |
The Johns Hopkins University |
Gene delivery system
|
|
IT1289608B1
(it)
*
|
1997-02-05 |
1998-10-15 |
Angelini Ricerche Spa |
Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
|
|
US6593369B2
(en)
|
1997-10-20 |
2003-07-15 |
Vivus, Inc. |
Methods, compositions, and kits for enhancing female sexual desire and responsiveness
|
|
US7087236B1
(en)
|
1998-09-01 |
2006-08-08 |
Merrion Research I Limited |
Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
|
|
AU759016B2
(en)
|
1998-10-05 |
2003-04-03 |
Penn State Research Foundation, The |
Compositions and methods for enhancing receptor-mediated cellular internalization
|
|
US20050153926A1
(en)
*
|
1998-12-04 |
2005-07-14 |
Adams Christopher P. |
Method for the immobilization of oligonucleotides
|
|
US7273618B2
(en)
*
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
US8114850B2
(en)
|
1999-04-08 |
2012-02-14 |
Advanced Cancer Therapeutics, Llc |
Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
|
|
US7960540B2
(en)
|
1999-04-08 |
2011-06-14 |
Advanced Cancer Therapeutics, Llc |
Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
|
|
EP1181304B1
(en)
|
1999-04-08 |
2007-10-10 |
Antisoma Research Limited |
Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
|
|
CA2398466A1
(en)
|
2000-01-27 |
2001-08-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6262020B1
(en)
*
|
2000-02-15 |
2001-07-17 |
Alphamed Pharmaceuticals Corp. |
Topical wound therapeutic compositions
|
|
EP2341075A1
(en)
*
|
2000-03-01 |
2011-07-06 |
MedImmune, LLC |
Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
|
|
CA2401239A1
(en)
*
|
2000-03-03 |
2001-09-13 |
Valentis, Inc. |
Improved poloxamer and poloxamine compositions for nucleic acid delivery
|
|
US6495164B1
(en)
*
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
US20040009940A1
(en)
*
|
2000-10-20 |
2004-01-15 |
Coleman Michael E. |
Gene delivery formulations and methods for treatment of ischemic conditions
|
|
EP2412384A1
(en)
|
2000-11-28 |
2012-02-01 |
MedImmune, LLC |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
|
US6848197B2
(en)
*
|
2001-04-18 |
2005-02-01 |
Advanced Inhalation Research, Inc. |
Control of process humidity to produce large, porous particles
|
|
US20030134810A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Chris Springate |
Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
|
|
WO2003046144A2
(en)
*
|
2001-11-26 |
2003-06-05 |
Molecular Reflections, Inc. |
Microscale immobilization of molecules using a hydrogel and methods of use thereof
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
WO2004010935A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Medimmune, Inc. |
Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
SI2301965T1
(sl)
|
2002-10-16 |
2015-07-31 |
Purdue Pharma L.P. |
Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
|
|
US7483738B2
(en)
*
|
2002-11-29 |
2009-01-27 |
Power Paper Ltd. |
Combination stimulating and exothermic heating device and method of use thereof
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
WO2004062619A2
(en)
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
JPWO2004078213A1
(ja)
*
|
2003-03-06 |
2006-06-08 |
千佳子 錦織 |
対象物質導入用組成物及び対象物質導入方法
|
|
JP4764818B2
(ja)
|
2003-04-11 |
2011-09-07 |
メディミューン，エルエルシー |
組換えｉｌ−９抗体およびその使用
|
|
US20050123550A1
(en)
*
|
2003-05-12 |
2005-06-09 |
Laurent Philippe E. |
Molecules enhancing dermal delivery of influenza vaccines
|
|
CA2528064C
(en)
*
|
2003-06-13 |
2010-01-12 |
Advanced Inhalation Research, Inc. |
Low dose pharmaceutical powders for inhalation
|
|
EP1660186B1
(en)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanization of antibodies
|
|
PT1684782E
(pt)
|
2003-10-03 |
2015-12-21 |
Thorn Bioscience Llc |
Processo para a sincronização da ovulação para reprodução regulada sem detecção do cio
|
|
WO2005092288A1
(en)
*
|
2004-03-19 |
2005-10-06 |
Let There Be Hope Medical Research Institute |
Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
|
|
CA2574977C
(en)
*
|
2004-07-29 |
2010-01-26 |
X-Sten, Corp. |
Spinal ligament modification devices
|
|
WO2006018899A1
(ja)
*
|
2004-08-17 |
2006-02-23 |
Bml, Inc. |
検出用器具を用いた検出方法
|
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
AU2005302453A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Llc |
Methods of preventing and treating RSV infections and related conditions
|
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン，エルエルシー |
抗体のフレームワーク・シャッフル
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
US20070003528A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Paul Consigny |
Intracoronary device and method of use thereof
|
|
CN103145839A
(zh)
*
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
JP2009502365A
(ja)
|
2005-07-29 |
2009-01-29 |
ヴァートス メディカル インコーポレーテッド |
経皮的組織切除装置および同方法
|
|
HUE029465T2
(en)
|
2005-08-10 |
2017-02-28 |
Macrogenics Inc |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
KR20130108481A
(ko)
|
2005-08-19 |
2013-10-02 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500356A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
|
PL2289909T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
|
|
US7942830B2
(en)
|
2006-05-09 |
2011-05-17 |
Vertos Medical, Inc. |
Ipsilateral approach to minimally invasive ligament decompression procedure
|
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
|
CA2914170C
(en)
|
2006-09-08 |
2018-10-30 |
Abbvie Bahamas Ltd. |
Interleukin-13 binding proteins
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
AU2007234612B2
(en)
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
AU2008246442B2
(en)
|
2007-05-04 |
2014-07-03 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
|
CN101801405A
(zh)
|
2007-08-07 |
2010-08-11 |
先进科技及再生医学有限责任公司 |
包含于酸性水溶液中的gdf-5的蛋白质配方
|
|
JP2011509675A
(ja)
|
2008-01-18 |
2011-03-31 |
メディミューン，エルエルシー |
部位特異的コンジュゲーションのためのシステイン操作抗体
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
BRPI0911048A2
(pt)
*
|
2008-04-14 |
2015-12-29 |
Atrm Llc |
formulações líquidas tamponadas de gdf-5
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
MX2010012142A
(es)
|
2008-05-09 |
2011-04-05 |
Abbott Gmbh & Co Kg |
Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
|
|
BRPI0913366A8
(pt)
|
2008-06-03 |
2017-07-11 |
Abbott Lab |
Imunoglobulinas de domínio variável duplo e seus usos
|
|
PE20100092A1
(es)
|
2008-06-03 |
2010-03-12 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
WO2010006059A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 binding proteins and uses thereof
|
|
NZ603698A
(en)
|
2008-07-08 |
2014-03-28 |
Abbvie Inc |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
|
USD619252S1
(en)
|
2008-10-23 |
2010-07-06 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD611146S1
(en)
|
2008-10-23 |
2010-03-02 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD619253S1
(en)
|
2008-10-23 |
2010-07-06 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD621939S1
(en)
|
2008-10-23 |
2010-08-17 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD610259S1
(en)
|
2008-10-23 |
2010-02-16 |
Vertos Medical, Inc. |
Tissue modification device
|
|
MX2011005953A
(es)
*
|
2008-12-04 |
2011-08-17 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual y usos de las mismas.
|
|
EP2376109B1
(en)
|
2008-12-19 |
2019-01-23 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
|
SG172855A1
(en)
*
|
2009-01-29 |
2011-08-29 |
Abbott Lab |
Il-1 binding proteins
|
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
|
US8283162B2
(en)
*
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
RU2568839C2
(ru)
|
2009-04-23 |
2015-11-20 |
ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК |
Способ и композиция для синхронизации времени осеменения
|
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
PL2464664T3
(pl)
|
2009-08-13 |
2016-02-29 |
Crucell Holland Bv |
Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
|
|
WO2011025964A2
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
AU2010306677B2
(en)
|
2009-10-15 |
2013-05-23 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
|
PE20130203A1
(es)
|
2010-03-17 |
2013-03-24 |
Abbott Res Bv |
Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
|
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
|
|
KR101539684B1
(ko)
|
2010-05-14 |
2015-07-27 |
애브비 인코포레이티드 |
Ｉｌ－１ 결합 단백질
|
|
EP2585094B1
(en)
|
2010-06-25 |
2018-08-01 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
PH12012502244A1
(en)
|
2010-07-09 |
2016-09-30 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
EP2601216B1
(en)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
US8735546B2
(en)
|
2010-08-03 |
2014-05-27 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
|
US9505829B2
(en)
|
2010-08-19 |
2016-11-29 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
NZ607337A
(en)
|
2010-08-20 |
2015-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
|
CN103517921B
(zh)
|
2010-12-21 |
2017-07-18 |
Abbvie 公司 |
IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
CA2836873C
(en)
|
2011-05-21 |
2019-10-22 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
EP2734236A4
(en)
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
|
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
JP2014533659A
(ja)
|
2011-10-24 |
2014-12-15 |
アッヴィ・インコーポレイテッド |
スクレロスチンに対するイムノバインダー
|
|
SG10201604104PA
(en)
|
2011-10-25 |
2016-07-28 |
Prothena Therapeutics Ltd |
Antibody formulations and methods
|
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
CN104144947B
(zh)
|
2011-12-14 |
2017-10-27 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
|
NZ714482A
(en)
|
2012-01-27 |
2017-08-25 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
|
EP2859018B1
(en)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Caninized anti-ngf antibodies and methods thereof
|
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
HK1216428A1
(zh)
|
2012-11-09 |
2016-11-11 |
辉瑞公司 |
血小板衍生生长因子b之特异性抗体及其组合物和用途
|
|
DK2925339T3
(da)
|
2012-11-28 |
2020-07-20 |
United Ah Ii Llc |
Fremgangsmåde til synkronisering af inseminationstidspunkt hos gylte
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
MX2015008117A
(es)
|
2012-12-21 |
2016-03-31 |
Amplimmune Inc |
Anticuerpos anti-h7cr.
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
|
|
CN113549148B
(zh)
|
2013-03-14 |
2025-11-21 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
SG11201509982UA
(2)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
KR20160055275A
(ko)
|
2013-09-17 |
2016-05-17 |
유니버시티 헬스 네트워크 |
시스 ｒｇｍａ/네오제닌 상호작용 또는 지질 래프트에 대해 지시되는 제제 및 치료 방법에서의 이의 용도
|
|
US10287572B2
(en)
|
2013-11-01 |
2019-05-14 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
|
MX388027B
(es)
|
2013-11-13 |
2025-03-19 |
Pfizer |
Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
|
|
WO2015084883A2
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
KR20160135190A
(ko)
|
2014-02-14 |
2016-11-25 |
앤드류 에스. 카이 |
혈관형성 암의 치료를 위한 개선된 방법
|
|
US10272117B2
(en)
|
2014-02-24 |
2019-04-30 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015138337A1
(en)
|
2014-03-09 |
2015-09-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
|
CA2940451A1
(en)
|
2014-03-12 |
2015-09-17 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
TWI731535B
(zh)
|
2014-03-21 |
2021-06-21 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
|
EP3142700B1
(en)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
CA2951532A1
(en)
*
|
2014-06-16 |
2015-12-23 |
Zoetis Services Llc |
Intravaginal formulations comprising gnrh
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
WO2016011167A1
(en)
|
2014-07-16 |
2016-01-21 |
Dana-Farber Cancer Institute, Inc., Et Al |
Her3 inhibition in low-grade serous ovarian cancers
|
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
US10689459B2
(en)
|
2014-12-12 |
2020-06-23 |
Novartis Ag |
Treatment of breast cancer brain metastases
|
|
US20160244520A1
(en)
|
2015-01-24 |
2016-08-25 |
Abbvie Inc. |
Compositions and methods for treating psoriatic arthritis
|
|
SG11201706024YA
(en)
|
2015-01-26 |
2017-08-30 |
Macrogenics Inc |
Multivalent molecules comprising dr5-binding domains
|
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
|
US10174121B2
(en)
|
2015-05-29 |
2019-01-08 |
Abbvie, Inc. |
Anti-CD40 antibodies
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
WO2017044862A1
(en)
|
2015-09-11 |
2017-03-16 |
Abbvie Inc. |
Methods for treating relapsing forms of multiple sclerosis
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
US11849741B2
(en)
|
2015-10-20 |
2023-12-26 |
Savage River, Inc. |
Meat-like food products
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
KR102815803B1
(ko)
|
2015-12-02 |
2025-06-05 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
|
CN114470194A
(zh)
|
2015-12-02 |
2022-05-13 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
TW201730212A
(zh)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
Ｒｏｒ１－結合分子及其使用方法
|
|
EP3423105B1
(en)
|
2016-03-02 |
2021-05-05 |
Eisai R&D Management Co., Ltd. |
Eribulin-based antibody-drug conjugates and methods of use
|
|
TWI781098B
(zh)
|
2016-04-15 |
2022-10-21 |
美商宏觀基因股份有限公司 |
新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
|
|
CN109496218A
(zh)
|
2016-06-01 |
2019-03-19 |
艾伯维公司 |
用于治疗脊髓损伤和疼痛的抗反义导向分子a（rgma）拮抗性抗体
|
|
BR112018075630A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de fármaco de anticorpo
|
|
EP3458479B1
(en)
|
2016-06-08 |
2020-11-04 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
EP3487521A4
(en)
|
2016-07-21 |
2020-07-01 |
Emory University |
ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
|
|
WO2018049078A1
(en)
|
2016-09-07 |
2018-03-15 |
Vertos Medical, Inc. |
Percutaneous lateral recess resection methods and instruments
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
|
JP2020513418A
(ja)
|
2016-12-13 |
2020-05-14 |
エモリー ユニバーシティ |
ウイルス感染を管理するためのポリペプチド
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
CA3045592A1
(en)
|
2016-12-21 |
2018-06-28 |
Novartis Ag |
Antibody drug conjugates for ablating hematopoietic stem cells
|
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
|
EP3574017A1
(en)
|
2017-01-27 |
2019-12-04 |
Kymab Limited |
Anti-opg antibodies
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
US12215151B2
(en)
|
2017-05-31 |
2025-02-04 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
CA3066918A1
(en)
|
2017-06-12 |
2018-12-20 |
Bluefin Biomedicine, Inc. |
Anti-il1rap antibodies and antibody drug conjugates
|
|
JP7685835B2
(ja)
|
2017-12-01 |
2025-05-30 |
ノバルティス アーゲー |
ポリオーマウイルス中和抗体
|
|
MX2020005662A
(es)
|
2017-12-01 |
2020-08-20 |
Pfizer |
Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
|
|
CA3090322A1
(en)
|
2018-02-12 |
2019-08-15 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human cd40 monoclonal antibodies
|
|
JP2021517461A
(ja)
|
2018-03-12 |
2021-07-26 |
ゾエティス・サービシーズ・エルエルシー |
抗ｎｇｆ抗体およびその方法
|
|
CA3094756A1
(en)
|
2018-03-29 |
2019-10-03 |
Pfizer Inc. |
Lfa3 variants and compositions and uses thereof
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
|
JOP20200268A1
(ar)
|
2018-06-01 |
2020-10-26 |
Eisai R&D Man Co Ltd |
تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
TW202014209A
(zh)
|
2018-06-20 |
2020-04-16 |
瑞士商諾華公司 |
用於消融造血幹細胞之抗體藥物軛合物
|
|
EP3826659B1
(en)
|
2018-07-10 |
2024-06-19 |
Rush University Medical Center |
Immunomodulator for use in the treatment of a bacterial infection
|
|
KR102767692B1
(ko)
|
2018-07-20 |
2025-02-17 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
US11359024B2
(en)
|
2018-09-07 |
2022-06-14 |
Pfizer Inc. |
Anti-AVB8 antibodies and compositions and uses thereof
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
WO2020069498A1
(en)
|
2018-09-28 |
2020-04-02 |
Jochen Reiser |
Supar and prediction and treatment of acute kidney injury
|
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
|
WO2020106358A1
(en)
|
2018-11-20 |
2020-05-28 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
|
PE20211473A1
(es)
|
2018-12-13 |
2021-08-05 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
|
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗ＴＮＦ－α抗體
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
JP7486497B2
(ja)
|
2019-01-16 |
2024-05-17 |
ユニバーシティ オブ ロチェスター |
上皮または内皮バリア機能の改善
|
|
JP7393810B2
(ja)
|
2019-03-08 |
2023-12-07 |
アブティス・カンパニー・リミテッド |
部位特異的抗体コンジュゲーション及びその具体例としての抗体－薬物コンジュゲート
|
|
US12291562B2
(en)
|
2019-04-01 |
2025-05-06 |
Rush University Medical Center |
Reagents and assays using modified integrin domains
|
|
KR20220010527A
(ko)
|
2019-05-20 |
2022-01-25 |
노파르티스 아게 |
친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
|
|
CN114729045B
(zh)
|
2019-09-26 |
2025-09-09 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
|
US12595304B2
(en)
|
2019-10-09 |
2026-04-07 |
Stcube & Co., Inc. |
Antibodies specific to glycosylated LAG3 and methods of use thereof
|
|
JP7657213B2
(ja)
|
2019-11-07 |
2025-04-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法
|
|
JP7449390B2
(ja)
|
2020-01-24 |
2024-03-13 |
ファイザー・インク |
抗ｅ－セレクチン抗体、組成物および使用の方法
|
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
|
WO2021231798A1
(en)
|
2020-05-13 |
2021-11-18 |
Disc Medicine, Inc. |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
JP2023528826A
(ja)
|
2020-05-29 |
2023-07-06 |
ウニヴェルジテート・ツー・ケルン |
Ｓａｒｓ関連コロナウイルスに対する中和抗体
|
|
AR122546A1
(es)
|
2020-06-05 |
2022-09-21 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
|
|
JP2023532888A
(ja)
|
2020-06-27 |
2023-08-01 |
クレセンタ バイオサイエンシズ |
細胞代謝を調節する化合物の組成及び使用方法
|
|
US11746154B2
(en)
|
2020-10-09 |
2023-09-05 |
Pfizer Inc. |
CD1a antibodies and uses thereof
|
|
GB202017058D0
(en)
|
2020-10-27 |
2020-12-09 |
Kymab Ltd |
Antibodies and uses thereof
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Ｆｃ変異体
|
|
CA3200858A1
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
|
EP4259200A1
(en)
|
2020-12-11 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Formulation for multi-purpose application
|
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
GB202101125D0
(en)
|
2021-01-27 |
2021-03-10 |
Kymab Ltd |
Antibodies and uses thereof
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
EP4423123A1
(en)
|
2021-10-28 |
2024-09-04 |
Novartis AG |
Engineered fc variants
|
|
GB202117111D0
(en)
|
2021-11-26 |
2022-01-12 |
Kymab Ltd |
Antibodies for use as therapeutics against bacterial infections
|
|
EP4190810A1
(en)
|
2021-12-01 |
2023-06-07 |
Universität zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
EP4441090A1
(en)
|
2021-12-01 |
2024-10-09 |
Universität zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
US12138243B2
(en)
|
2021-12-31 |
2024-11-12 |
Crescenta Biosciences |
Antiviral use of FABP4 modulating compounds
|
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
WO2023245144A1
(en)
|
2022-06-16 |
2023-12-21 |
Vertos Medical, Inc. |
Integrated instrument assembly
|
|
CA3262035A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
|
|
EP4565330A1
(en)
|
2022-08-05 |
2025-06-11 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
|
CN120051495A
(zh)
|
2022-08-05 |
2025-05-27 |
詹森生物科技公司 |
用于治疗脑肿瘤的cd98结合构建体
|
|
KR20250134734A
(ko)
|
2022-12-16 |
2025-09-11 |
페온 테라퓨틱스 리미티드 |
Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
|
|
WO2024160721A1
(en)
|
2023-01-30 |
2024-08-08 |
Kymab Limited |
Antibodies
|
|
EP4669667A2
(en)
|
2023-02-24 |
2025-12-31 |
Universität zu Köln |
SARS-CoV-2 Neutralizing Antibodies
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
AU2024307442A1
(en)
|
2023-06-28 |
2026-02-19 |
Universität Zu Köln |
Neutralizing human monoclonal antibodies against p. aeruginosa
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|